Susan Bressman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4077927/publications.pdf

Version: 2024-02-01

33 papers	3,418 citations	361045 20 h-index	395343 33 g-index
33 all docs	33 docs citations	33 times ranked	5217 citing authors

#	Article	IF	Citations
1	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	4.9	1,340
2	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	1.7	330
3	Functional variants in the LRRK2 gene confer shared effects on risk for Crohnâ€™s disease and Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	5.8	273
4	Antiâ€“Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA Neurology, 2018, 75, 939.	4.5	256
5	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nature Communications, 2014, 5, 4835.	5.8	156
6	A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci. PLoS Genetics, 2012, 8, e1002559.	1.5	144
7	Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations. Movement Disorders, 2013, 28, 1966-1971.	2.2	131
8	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	4.9	94
9	Higher Frequency of Certain Cancers inLRRK2G2019S Mutation Carriers With Parkinson Disease. JAMA Neurology, 2015, 72, 58.	4.5	76
10	Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2Î± Signaling as a Generalizable Mechanism for Dystonia. Neuron, 2016, 92, 1238-1251.	3.8	68
11	Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 106-110.	1.1	58
12	Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764.	2.2	57
13	Neuropsychiatric characteristics of GBA-associated Parkinson disease. Journal of the Neurological Sciences, 2016, 370, 63-69.	0.3	50
14	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Crossâ€Sectional Study. Movement Disorders, 2020, 35, 833-844.	2.2	48
15	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in <scp>GBA</scp> Mutation Carriers. Annals of Neurology, 2022, 91, 424-435.	2.8	46
16	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Annals of Neurology, 2000, 47, 369-373.	2.8	41
17	Glucocerebrosidase enzyme activity in GBA mutation Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2016, 28, 185-186.	0.8	33
18	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	2.8	30

#	Article	IF	Citations
19	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Movement Disorders, 2019, 34, 1392-1398.	2.2	28
20	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. Human Genetics, 2018, 137, 343-355.	1.8	24
21	A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. Brain Structure and Function, 2017, 222, 1207-1218.	1.2	22
22	Cervical Dystonia Incidence and Diagnostic Delay in a Multiethnic Population. Movement Disorders, 2020, 35, 450-456.	2.2	22
23	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. Neuron, 2021, 109, 1465-1478.e4.	3.8	21
24	Intact working memory in nonâ€manifesting <scp>LRRK</scp>2 carriers â€“ an <scp>fMRI</scp> study. European Journal of Neuroscience, 2016, 43, 106-112.	1.2	16
25	Dysregulation of mitochondrial and proteolysosomal genes in Parkinsonâ€™s disease myeloid cells. Nature Aging, 2021, 1, 850-863.	5.3	16
26	Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease. Frontiers in Neurology, 2019, 10, 531.	1.1	13
27	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. Genetics in Medicine, 2014, 16, 644-645.	1.1	7
28	Efficient estimation of nonparametric genetic risk function with censored data. Biometrika, 2015, 102, 515-532.	1.3	5
29	Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients. Clinical Parkinsonism & Related Disorders, 2020, 3, 100042.	0.5	4
30	The minimal clinically important change in the motor section of the Burke-Fahn-Marsden Dystonia Rating Scale for generalized dystonia: Results from deep brain stimulation. Parkinsonism and Related Disorders, 2021, 93, 85-88.	1.1	3
31	Refractory Seizures Secondary to Vitamin B6 Deficiency in Parkinson Disease: The Role of Carbidopa-Levodopa. Case Reports in Neurology, 2022, 14, 291-295.	0.3	3
32	Deep Brain Stimulation of the Pallidofugal Pathways to Rescue Severe Life-Threatening Dyskinesias after STN-DBS Lead Implantation. Stereotactic and Functional Neurosurgery, 2022, 100, 95-98.	0.8	2
33	Increased substantia nigra echogenicity in LRRK2 family members without mutations. Movement Disorders, 2018, 33, 1504-1505.	2.2	1